Mackenzie Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Mackenzie Financial’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,195	Closed	-$227K	–	1604
2025 Q4	$227K	Buy	1,195 +26	+2%	+$5K	﹤0.01%	1494
2025 Q3	$207K	Buy	+1,169	New	+$174K	﹤0.01%	1551
2020 Q3	–	Sell	-4,046	Closed	-$282K	–	1025
2020 Q2	$282K	Sell	4,046 -36,478	-90%	-$2.31M	﹤0.01%	883
2020 Q1	$1.84M	Buy	+40,524	New	+$2.3M	0.01%	518
2019 Q1	–	Sell	-35,085	Closed	-$2.97M	–	1280
2018 Q4	$2.97M	Sell	35,085 -22,787	-39%	-$2.43M	0.01%	628
2018 Q3	$9.91M	Buy	+57,872	New	+$8.72M	0.02%	333
2016 Q3	–	Sell	-35,492	Closed	-$2.64M	–	776
2016 Q2	$2.64M	Sell	35,492 -160	-0.4%	-$11.9K	0.01%	395
2016 Q1	$2.38M	Buy	+35,652	New	+$2.17M	0.02%	332

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Mackenzie Financial's LGND Position: Q1 2026 in Review

Mackenzie Financial sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,195 shares — an estimated $227K sold.

Mackenzie Financial first reported a position in LGND in Q1 2016 and held it in 8 quarters. The position peaked at $9.91M in Q3 2018. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Mackenzie Financial reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Mackenzie Financial sold 1,195 Ligand Pharmaceuticals shares in Q1 2026, an estimated $227K.
Mackenzie Financial first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Mackenzie Financial's Ligand Pharmaceuticals position peaked at $9.91M in Q3 2018.
358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.